VALIDIAN CORP Form 10-Q November 20, 2017

OMB APPROVAL OMB Number: 3235-0070

Expires: September 30, 2018

Estimated average burden

hours per response 187.43

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 10-Q

(Mark One)

X

QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

For the quarterly period ended September 30, 2017

OR

TRANSITION REPORT PURSUANT TO SECTION 13 OR 15 (d) OF THE

SECURITIES EXCHANGE ACT OF 1934

For the transition period from to

Commission File No. <u>000-28423</u>

VALIDIAN CORPORATION

(Exact name of Registrant as specified in its charter)

NEVADA

58-2541997

(State or other jurisdiction of incorporation or organization)

(I.R.S. Employer Identification No.)

6 Gurdwara Rd., Suite 205, Ottawa, Ontario, Canada K2E 8A3

(Address of principal executive offices)

Registrant s telephone number: 613-230-7211

Check whether the issuer (1) filed all reports required to be filed by Section 13 or 15(d) of the Exchange Act during the past 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days. Yes xNo "

Indicate by check mark whether the registrant has submitted electronically and posted on its corporate Web site, if any, every Interactive Data File required to be submitted and posted pursuant to Rule 405 of Regulation S-T (§232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit and post such files). Yes x No "

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company or an emerging growth company. See the definitions of "large accelerated filer," "accelerated filer , smaller reporting company and emerging growth company in Rule 12b-2 of the Exchange Act:

Large Accelerated Filer £ Accelerated Filer £

Non-Accelerated Filer £ Small Reporting Company S

(Do not check if a smaller reporting company) Emerging Growth Company £

Indicated by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act):

Yes " No x

APPLICABLE ONLY TO CORPORATE ISSUERS:

At November 15, 2017, 566,740,260 shares of the registrant's common stock were outstanding.

SEC 1296 (1-12)

Potential persons who are to respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB control number.

1

PART I FINANCIAL INFORMATION

Item 1. Financial Statements

VALIDIAN CORPORATION AND SUBSIDIARIES

Unaudited Interim Consolidated, Condensed Balance Sheets

(In United States dollars) September 30,

	2017	December 31, 2016
Assets		
Current assets:		
Cash and cash equivalents	\$ 160	\$ 191,764
Value added taxes recoverable	5,093	34,020
Prepaid expenses	3,568	57,544
Total Current assets	8,821	283,328
Total assets	\$ 8,821	\$ 283,328
Liabilities and Stockholders Deficiency Current liabilities:		
Accounts payable and accrued liabilities (note 8)	\$ 2,983,810	\$ 2,563,820
Accrued interest on 10% senior convertible notes	ψ 2,763,610	ψ 2,303,620
11001000 11001000 011 10 /0 001101 0011 011010 11000		
payable to related parties (note 8)	4,001	4,001
Deferred revenue	320,000	320,000
Promissory notes payable (notes 2, 8)	61,250	112,784
Promissory notes payable to a related party (notes		
3, 8)	6,000	
10% Senior convertible notes (notes 3, 8)	1,168,974	962,739
Convertible promissory notes (note 4)	84,308	32,777
Total current liabilities	4,628,343	3,996,121
Total liabilities	4,628,343	3,996,121
Stockholders deficiency (note 5): Preferred stock (\$0.001 par value. Authorized 50,000,000 shares; issued		
and outstanding Nil shares at September 30, 2017 and at December 31,		
2016)	-	-
Series A Convertible Preferred stock (\$0.001 par value, \$1,000 stated value.	2	2

4

3

Authorized 10,000 shares; issued and outstanding 2,230 shares at

September 30, 2017 and December 31, 2016) Series B Convertible Preferred stock (\$0.001 par value, \$1,000 stated value.

Authorized 5,000 shares; issued and outstanding 3,900 shares at

September 30, 2017 and December 31, 2016) Series C Convertible Preferred stock (\$0.001 par value, \$1,000 stated value.

Authorized 5,000 shares; issued and outstanding 3,229 shares at

September 30, 2017 and December 31, 2016) Common stock, (\$0.001 par value. Authorized 700,000,000 shares;

issued and outstanding 566,740,260 and 442,341,498 shares at

 September 30, 2017 and December 31, 2016,

 respectively.)
 566,740
 442,342

 Additional paid in capital
 49,431,625
 48,555,010

 Deficit
 (54,568,158)
 (52,660,416)

Treasury stock (7,000 shares at September 30, 2017 and December 31, 2016,

at cost) (49,738) (49,738)
Total stockholders deficiency (4,619,522) (3,712,793)

Basis of presentation (note 1) Subsequent events (note 12)

Total liabilities and stockholders deficiency \$ 8,821 \$ 283,328

See accompanying notes to unaudited interim consolidated financial statements.

4


3

VALIDIAN CORPORATION AND SUBSIDIARIES

Unaudited Interim Consolidated, Condensed Statements of Operations

For the three and nine months ended September 30, 2017 and 2016

	(In United States Three Month		Nine Month	s Ended
2017	September 20	•	September 20	•
Expenses:				
Selling, general and administrative	\$ 140,542	\$ 212,437	\$ 382,978	\$ 651,936
Research and development	30,107	227,017	497,923	686,112
Total expenses	170,649	439,454	880,901	1,338,048
Loss before the undernoted	(170,649)	(439,454)	(880,901)	(1,338,048)
Other income (expenses):				
Loss on extinguishment of debt				(1,750,294)
Interest and financing costs (notes 6 and			(891,641)	
8)	(336,800)	(471,112)		(1,116,246)
Foreign exchange gain (loss)	(73,081)	18,460	(135,200)	(77,438)
Total other income (expenses)	(409,881)	(452,652)	(1,026,841)	(2,943,978)
Net loss	\$ (580,530)	\$ (892,106)	\$ (1,907,742)	\$ (4,282,026)
Loss per common share basic and diluted			\$(0.00)	
(note 7)	\$(0.00)	\$(0.00)		\$(0.01)
Weighted average number of common				
shares outstanding during period	520,345,061	420,624,008	473,967,374	409,198,184



VALIDIAN CORPORATION AND SUBSIDIARIES

Unaudited Interim Consolidated, Condensed Statements of Cash Flow

For the nine months ended September 30, 2017 and 2016

(In United States dollars)

Nine months Ended

	2017	Septe	mber 30, 2016	
Cash flows from operating activities:				
Net loss		\$ (1,907,74)	2)	\$ (4,282,026)
Adjustments to reconcile net loss to net cash used in				
operating activities:				
Stock-based compensation		53,97	76	378,325
Non-cash interest and financing expense		844,25	51	605,064
Loss on extinguishment of debt				1,750,294
Increase (decrease) in cash resulting from changes in:				
Value added taxes recoverable		28,92	27	(10,331)
Prepaid expenses				(3,064)
Accounts payable and accrued liabilities		473,74	19	173,287
Net cash used in operating activities		(506,839	9)	(1,388,451)
Cash flows from investing activities:				
Net cash used in investing activities				
Cash flows from financing activities:				
Issuance of Class A Convertible Preferred Stock				1,225,000
Issuance of 10% senior convertible notes		151,23	35	70,000
Issuance of convertible promissory notes		321,00	00	748,611
Issuance of promissory notes		31,00	00	82,500
Debt issuance costs		(14,50	0)	(27,750)
Original issue discount		(15,00	0)	(36,611)
Repayment of 10% senior convertible notes		(5,00	0)	(38,452)
Repayment of convertible promissory notes		(71,00	0)	(316,111)
Repayment of promissory notes		(82,50	0)	
Net cash provided by financing activities		315,23	35	1,707,187
Net increase (decrease) in cash and cash equivalents		(191,60	4)	318,736
Cash and cash equivalents:				
Beginning of period		191,76	54	38,458
End of period		\$ 16	50	\$ 357,194

Supplementary information (note 9)

See accompanying notes to unaudited interim consolidated financial statements.

VALIDIAN CORPORATION AND SUBSIDIARIES

Notes to Unaudited Interim Consolidated, Condensed Financial Statements

September 30, 2017

(In United States dollars)

Validian Corporation (the Company) was incorporated in the State of Nevada on April 12, 1989 as CCC Funding Corp. The Company underwent several name changes before being renamed to Validian Corporation on January 28, 2003.

Since August 3, 1999, the efforts of the Company have been devoted primarily to the development of a high speed, highly secure method of transacting business using the Internet, and to the sale and marketing of the Company s products.

1. Basis of presentation

The accompanying consolidated financial statements include the accounts of Validian Corporation and its wholly owned subsidiaries (collectively, the "Company") after elimination of all significant intercompany balances and transactions. The financial statements have been prepared in conformity with generally accepted accounting principles in the United States of America which require management to make estimates and assumptions that affect the amounts reported in the financial statements and accompanying notes. While management has based its assumptions and estimates on the facts and circumstances currently known, final amounts may differ from such estimates.

The interim financial statements are unaudited but, in the opinion of management, include all adjustments (consisting only of normal recurring entries) necessary for a fair presentation of the financial position and results of operations of the Company for the periods presented. The results of operations for the nine months ended September 30, 2017 are not necessarily indicative of the operating results for the full fiscal year ending December 31, 2017. These unaudited interim financial statements have been prepared following accounting principles consistent with those used in the annual audited financial statements and should be read in conjunction with the annual audited financial statements for the year ended December 31, 2016.

Going concern

The consolidated financial statements have been prepared assuming that the Company will continue as a going concern. The Company has no revenues, has negative working capital of \$4,619,522, and stockholders deficiency of \$4,619,522 as at September 30, 2017, and has incurred a loss of \$1,907,742 and negative cash flow from operations of \$506,839 for the nine months then ended. Furthermore, the Company failed to settle certain 10% senior convertible notes, convertible promissory notes and promissory notes plus accrued interest when they matured on various dates between October 2008 and September 2017. As a result of these non-payment defaults, all of the 10% senior convertible notes, the promissory notes, and \$64,700 of the convertible promissory notes were in default at September 30, 2017, in accordance with the default provisions of the respective notes, and consequently are due and payable on demand. In addition, the Company expects to continue to incur operating losses for the foreseeable future, and has no lines of credit or other financing facilities in place.

The Company expects to incur operating expenses of approximately \$1,472,000 for the year ending December 31, 2017, subject to the availability of adequate funding. In the event the Company cannot raise the additional funds necessary to finance its research and development and sales and marketing activities, it may have to cease operations.

All of the factors above raise substantial doubt about the Company s ability to continue as a going concern. Management s plan to address these issues includes raising capital through the private placement of equity, the exercise of previously-issued equity instruments and through the issuance of additional promissory notes. The Company s ability to continue as a going concern is subject to management s ability to successfully implement these plans. Failure to do so could have a material adverse effect on the Company s position and or results of operations and could also result in the Company ceasing operations. The consolidated financial statements do not include adjustments that would be required if the assets are not realized and the liabilities settled in the normal course of operations.

Even if successful in obtaining financing in the near term, the Company cannot be certain that cash generated from its future operations will be sufficient to satisfy its liquidity requirements in the longer term, and it may need to continue to raise capital by issuing additional equity or by obtaining credit facilities. The Company s future capital requirements will depend on many factors, including, but not limited to, the market acceptance of its products and the level of its promotional activities and advertising required to generate product sales. No assurance can be given that any such additional funding will be available or that, if available, it can be obtained on terms favorable to the Company.

VALIDIAN CORPORATION AND SUBSIDIARIES

Notes to Unaudited Interim Consolidated, Condensed Financial Statements

September 30, 2017

(In United States dollars)

2. Promissory notes payable

The following table sets forth the financial statement presentation of the promissory note proceeds on issuance, and the changes in the financial statement presentation of the balance allocated to the notes as at and for the periods ended September 30, 2017 and December 31, 2016:

	Nine months	Year ended
	ended September 30, 2017	December 31, 2016
	(unaudited)	2010
Balance beginning of period	\$ 116,652	\$ 36,250
Note proceeds on issuance	31,000	82,500
Allocated to common stock and additional paid-in capital for the relative fair value of stock issued to holders of the notes:		
Allocated to common stock par value	(75)	(750)
Allocated to additional paid-in capital	(1,506)	(21,250)
	(1,581)	(22,000)
Proceeds allocated to promissory notes on issuance	29,419	60,500
Accretion recorded as a charge to interest and financing costs	3,679	19,902
Principal repaid	(82,500)	
Balance end of period	67,250	116,652
Payable to a related party (note 8)	(6,000)	
Deferred finance charges		(3,868)
Balance end of period, net of deferred finance charges	\$ 61,250	\$ 112,784

During the nine months ended September 30, 2017, the Company issued \$31,000 of its promissory notes. The notes are payable on demand, and bear interest at the rate of 12% per annum. The Company issued 75,000 shares of its common stock to the investors at issuance; \$1,581, representing the relative fair value of the shares, was charged to common stock and additional paid in capital.

During the nine months ended September 30, 2017, the Company also repaid \$82,500 of the promissory notes, and \$3,526 in accrued interest charges thereon.

The notes outstanding at September 30, 2017 bear interest at the rate of 12% per annum.

Included in interest and financing costs for the three and nine months ended September 30, 2017 is \$1,768 (2016: \$2,249) and \$4,885 (2016: \$4,418), respectively, of interest on the promissory notes; \$nil (2016: \$6,584) and \$3,679 (2016: \$6,584), respectively, of accretion charges; and \$nil (2016: \$419) and \$3,868 (2016: \$419), respectively, of finance fees. Interest on the promissory notes paid in cash during the three and nine months ended September 30, 2016 is \$nil (2016: \$6,000) and \$3,526 (2016: \$6,000), respectively.

VALIDIAN CORPORATION AND SUBSIDIARIES

Notes to Unaudited Interim Consolidated, Condensed Financial Statements

September 30, 2017

(In United States dollars)

3. 10% Senior convertible notes

The following table sets forth the financial statement presentation of the note proceeds on issuance, and the changes in financial statement presentation of the balance allocated to the 10% senior convertible notes for the periods ended September 30, 2017 and December 31, 2016:

	Nine months Ended September 30,	D	Year Ended ecember 31,
	2017		2016
Balance beginning of period	\$ (unaudited) 962,739	\$	6,721,291
Note proceeds on issuance	211,235		70,000
Allocated to common stock and additional paid-in capital for the relative			
fair value of stock issued to holders of the notes:			
Allocated to common stock par value	(8,999)		(210)
Allocated to additional paid-in capital	(54,578)		(5,996)
	(63,577)		(6,206)
Allocated to additional paid-in capital for the intrinsic value of the			
beneficial conversion feature			(11,873)
Proceeds allocated to 10% senior convertible notes on issuance	147,658		51,921
Accretion recorded as a charge to interest and financing costs	63,577		18,079
Principal repaid in cash	(5,000)		(49,794)
Principal converted in accordance with the terms of the notes			(151,500)
Principal settled through the issuance of Series B convertible preferred stock			(2,835,025)
Principal settled through the issuance of Series C convertible preferred stock			(2,792,233)

Balance end of period \$ 1,168,974 \$ 962,739

During the nine months ended September 30, 2017, the Company issued \$211,235 of its senior convertible notes, and repaid \$5,000 in principal. \$151,235 of the notes were issued for cash; \$60,000 of the notes were issued in settlement of accounts payable and accrued liabilities.

Under the terms of the notes issued during the nine months ended September 30, 2017, the holders are permitted, at any time, to convert all or a portion of the outstanding principal plus accrued interest into common stock of the company, at a rate of one common share for each \$0.03 of debt converted. The Company has the option of pre-paying all or any portion of the balance outstanding on the notes at any time, without penalty or bonus, with the permission of the holders. Interest on the notes is accrued until the notes are either repaid by the Company or converted by the holder. At the Company s option, interest may be paid either in cash or in common shares of the Company. If interest is paid in common shares, the number of shares required for settlement will be calculated at the rate of conversion in effect for the conversion of the note principal. The notes mature on December 31, 2017.

Holders of the notes issued during the nine months ended September 30, 2017 were granted 8,999,001 common shares of the Company upon issuance of the notes; \$63,577, representing the relative fair value of the common shares at the issuance date, was allocated to the common shares par value and additional paid in capital.

Notwithstanding the stated maturity dates, all of the senior convertible notes are payable on demand, pursuant to the default provisions of the notes, as described below.

The Company failed to settle certain of its 10% senior convertible notes plus accrued interest thereon when they matured on various dates between October 1, 2008 and December 31, 2016. At September 30, 2017, a significant portion of these notes remained in default for non-payment. As a result of these non-payment defaults, all of the 10% senior convertible notes are in default at September 30, 2017, in accordance with the default provisions of the notes, and consequently are payable on demand. Interest is accrued at the coupon rate on all notes outstanding past the maturity date.

VALIDIAN CORPORATION AND SUBSIDIARIES

Notes to Unaudited Interim Consolidated, Condensed Financial Statements

September 30, 2017

(In United States dollars)

3. 10% Senior convertible notes (continued)

The notes are unsecured, and are convertible as follows:

Note	Conversion
Principal	Rate
\$ 662,467	\$0.03
6,506	0.038
500,000	0.10
\$ 1,168,974	

Included in interest and financing costs for the three and nine months ended September 30, 2017 is \$27,732 (2016: \$29,567) and \$76,190 (2016: \$337,399), respectively, in coupon rate interest accrued on the 10% senior convertible notes, and \$47,190 (2016: \$nil) and \$63,577 (2016: \$18,079), respectively, in accretion related to the relative fair value of the equity components of the 10% senior convertible notes at issuance.

At September 30, 2017, the fair value of the stock issuable to fully convert the 10% senior convertible note principal, was \$226,203, which is \$942,769 less than the principal outstanding on that date.

4. Convertible promissory notes

During the nine months ended September 30, 2017, the Company issued \$321,000 of its convertible promissory notes for cash.

\$60,000 of the notes issued during the nine months ended September 30, 2017 bear interest at the rate of 8%, mature on July 17, 2018, and may be prepaid during the period from issuance to January 13, 2018, in full, at various rates ranging from 125% to 145% of the principal balance plus accrued interest to the date of prepayment. The holder has the option to convert any balance of principal and interest which is unpaid at January 13, 2018, or thereafter, into common stock of the Company. The rate of conversion for these notes is calculated as the average of the three lowest trading price during the twenty trading days immediately preceding such conversion, discounted by 45%.

\$105,000 of the notes issued during the nine months ended September 30, 2017 bear interest at the rate of 8%, mature on June 12, 2018, and may be prepaid during the period from issuance to December 8, 2017, in full, at various rates ranging from 125% to 145% of the principal balance plus accrued interest to the date of prepayment. The holder has the option to convert any balance of principal and interest which is unpaid at December 8, 2017, or thereafter, into common stock of the Company. The rate of conversion for these notes is calculated as the lowest trading price during the ten trading days immediately preceding such conversion, including the date of conversion, discounted by 45%.

\$78,000 of the notes issued during the nine months ended September 30, 2017 bear interest at the rate of 8%, mature on November 10 2017, and could be prepaid during the period from issuance to August 2, 2017, in full, at various rates ranging from 125% to 145% of the principal balance plus accrued interest to the date of prepayment. The holder had the option to convert any balance of principal and interest which was unpaid at August 2, 2017, or thereafter, into common stock of the Company. The rate of conversion for these notes was calculated as the average of the lowest three trading prices during the ten trading days immediately preceding such conversion, discounted by 42%.

\$35,000 of the notes issued during the nine months ended September 30, 2017 bear interest at the rate of 8%, mature on February 12, 2018, and can be prepaid during the period from issuance to August 11, 2017, in full, at various rates ranging from 125% to 145% of the principal balance plus accrued interest to the date of prepayment. The holder has the option to convert any balance of principal and interest which is unpaid at August 11, 2017, or thereafter, into common stock of the Company. The rate of conversion for these notes is calculated as the average of the lowest three trading prices during the twenty trading days immediately preceding such conversion, discounted by 45%.

\$43,000 of the notes issued during the nine months ended September 30, 2017 bear interest at the rate of 12%, mature on November 30, 2017, and could be prepaid during the period from issuance to August 16, 2017, in full, at various rates ranging from 125% to 145% of the principal balance plus accrued interest to the date of prepayment. The holder had the option to convert any balance of principal and interest which was unpaid at August 16, 2017, or thereafter, into common stock of the Company. The rate of conversion

VALIDIAN CORPORATION AND SUBSIDIARIES

Notes to Unaudited Interim Consolidated, Condensed Financial Statements

September 30, 2017

(In United States dollars)

4. Convertible promissory notes (continued)

for these notes was calculated as the average of the lowest three trading prices during the ten trading days immediately preceding such conversion, discounted by 42%.

\$265,196, representing the relative fair value of the beneficial conversion feature of the notes at date of issuance, was allocated to additional paid in capital; the notes are being accreted to their face value over the term of the notes, through periodic charges to interest expense using the effective interest rate method.

\$14,500 in finance fees, and \$15,000 in original issue discounts, were incurred in relation to the convertible promissory notes issued during the nine months ended September 30, 2017, and are being charged to interest and financing costs over the term of the notes, using the effective interest rate method.

During the nine months ended September 30, 2017, holders of the convertible promissory notes exercised the conversion feature of the notes, and converted \$571,887 of note principal, plus \$20,771 of accrued interest thereon, into 115,374,761 shares of the Company s common stock.

The convertible promissory notes contain penalty provisions relating to events of default, pursuant to which the Company could be required not only to pay interest at the rate of 22% following such an event, but also to pay immediately 150% of the principal outstanding plus accrued interest and penalty interest; alternatively, the Company could be required, at the discretion of the holder, to issue stock in satisfaction of the value determined under such penalty provisions, at the rate of conversion in effect at such time as the holder so elects. In addition to non-payment of the note principal and interest at maturity or failure to transfer stock on receipt of a notice of conversion from the holder, events of default include making an assignment or appointment of a receiver or trustee, ceasing operations, liquidating assets or entering into bankruptcy proceedings; certain money judgments filed against the Company; breach of covenants, representations or warranties under the note; delisting of the Company s stock or failure to comply with the exchange act; failure to maintain property or rights which are necessary to the Company s business; certain restatements of the Company s financial statements as filed with the SEC during the preceding two years; effectuating a reverse stock split without first providing the holder with 20 days notice of such occurrence; replacing

the Company s transfer agent without first providing to the successor transfer agent, the necessary instructions to effect a transfer of stock to the holder pursuant to the terms of the note.

The discount to market conversion feature of the convertible promissory notes causes a theoretical possibility that the Company may be required to settle the notes by issuing more shares than are authorized. Management has calculated that the maximum number of shares required to convert the principal plus accrued interest on the convertible notes at September 30, 2017 was 81,264,137, which represents approximately 61% of the authorized, unissued shares at that date, and has also estimated that the fair value of the notes at September 30, 2017 approximates face value, therefore no adjustment for fair value restatement has been made.

The convertible promissory notes are being accreted to their face value over the term of the notes through periodic charges to interest expense. During the three and nine months ended September 30, 2017, accretion of \$175,437 (2016: \$279,043) and \$613,874 (2016: \$533,597), respectively was included in interest and financing costs.

Also included in interest and financing costs for the three and nine months ended September 30, 2017 is \$45,921 (2016: \$126,897) and \$71,328 (2016: \$171,653), respectively, relating to accrued coupon-rate and bonus interest on the convertible promissory notes; and \$38,752 (2016: \$26,355) and \$54,240 (2016: \$44,099), respectively, relating to the amortization of deferred finance fees and original issue discount incurred in connection with the placement of the convertible promissory notes. At September 30, 2016, the fair value of the stock issuable to fully convert the convertible promissory note principal was \$634,853, which exceeded the principal amount outstanding on that date by \$369,241.

VALIDIAN CORPORATION AND SUBSIDIARIES

Notes to Unaudited Interim Consolidated, Condensed Financial Statements

September 30, 2017

(In United States dollars)

5. Stockholders deficiency
(a) Common stock transactions
During the nine months ended September 30, 2017, holders of the convertible promissory notes exercised the conversion feature of the notes and converted an aggregate of \$571,887 of note principal, plus \$20,771 of accrued interest thereon, into 115,374,761 shares of the Company s common stock.
In connection with the issuance of the Company s 10% senior convertible notes during the nine months ended September 30, 2017, the Company issued 8,999,001 shares of its common stock, with a relative fair value of \$63,577, to the holders of the notes.
In connection with the issuance of the Company s promissory notes during the nine months ended September 30, 2017, the Company issued 75,000 shares of its common stock, with a relative fair value of \$1,581, to the holders of the notes.
(b) Preferred stock transactions

During the nine months ended September 30, 2017, the Company issued 78 of its Series C preferred shares in

settlement of \$78,000 of accounts payable and accrued liabilities.

(c)

Stock-based compensation

The following table presents the total of stock-based compensation included in the expenses of the Company for the three and nine months ended September 30, 2017 and 2016:

	Thre	ee month	s ended	N	line months	s ended
	S	Septembe	er 30,		Septembe	r 30,
		2017	2016		2017	2016
Selling, general and administrative	\$	504	\$ 114,329	\$	53,976	\$ 378,325
Research and development						
Total stock-based compensation included in expenses	\$	504	\$ 114,329	\$	53,976	\$ 378,325

6. Interest and financing costs

Interest and financing costs include accrued and paid coupon rate interest and accretion and financing costs relating to the 10% senior convertible notes, promissory notes and convertible promissory notes.

VALIDIAN CORPORATION AND SUBSIDIARIES

Notes to Unaudited Interim Consolidated, Condensed Financial Statements

September 30, 2017

(In United States dollars)

7. Loss per share

As the Company incurred a net loss during the nine months ended September 30, 2017, and during the nine months ended September 30, 2016, the loss and diluted loss per common share are based on the weighted-average common shares outstanding during the period. The following outstanding instruments could have a dilutive effect in the future:

	September 30,	September 30,
	2017	2016
	(unaudited)	(unaudited)
Shares issuable on conversion of 10% senior convertible notes	27,253,434	36,379,793
Shares issuable on conversion of convertible promissory		
notes and accrued interest thereon	81,264,137	17,743,598
Common shares issuable on conversion of the Series A		
convertible preferred stock	22,300,000	22,300,000
Common shares issuable on conversion of the Series B		
convertible preferred stock	130,000,000	130,000,000
Common shares issuable on conversion of the Series C		
convertible preferred stock	107,633,333	106,166,667
Stock options	7,500,000	7,500,000
Total	375,950,904	320,090,058

8. Related party transactions

\$4,001 (December 31, 2016: \$4,001) in accrued interest charges relating to the 10% senior convertible notes previously issued to a director and a company controlled by a director is included in accrued liabilities at September 30, 2017. \$\frac{1}{2016}: \frac{1}{2016}: \frac{1}{2016}: \frac{24,007}{2016}: \frac{1}{2016}: \frac{1}{20

An officer and director of a company who holds \$6,000 (December 31, 2016: \$nil) of the promissory notes is also an officer and director of the Company.

VALIDIAN CORPORATION AND SUBSIDIARIES

Notes to Unaudited Interim Consolidated, Condensed Financial Statements

September 30, 2017

(In United States dollars)

9. Supplementary cash flow information

The Company paid no income taxes during the nine months ended September 30, 2017, nor during the nine months ended September 30, 2016. Interest paid in cash during the nine months ended September 30, 2017 was \$47,390 (2016: \$511,182).

Non-cash financing activities are excluded from the consolidated statements of cash flows. The following is a summary of such activities for the nine months ended September 30, 2017 and 2016:

	2	017	2	016
Issuance of the Company s common stock on conversion of convertible promissory notes plus accrued interest thereon	\$	592,659	\$	297,392
Issuance of the Company s Series C convertible preferred stock in settlement		= 0.000		
of accounts payable and accrued liabilities		78,000		
Issuance of the Company s 10% senior convertible notes in settlement of				
accounts payable and accrued liabilities		60,000		
Issuance of the Company s common stock as compensation to consultants				283,330
Issuance of the Company s common stock in settlement of accounts payable				
and accrued liabilities				6,000
Issuance of the Company s common stock on conversion of the 10% senior				
convertible notes plus accrued interest thereon				98,034
Issuance of the Company s Series A convertible preferred stock in settlement				
of accrued interest on the 10% senior convertible notes				792,355
Issuance of the Company s Series B convertible preferred stock in settlement				
of 10% senior convertible notes plus accrued interest thereon				3,083,875
Issuance of the Company s Series C convertible preferred stock in settlement				
of 10% senior convertible notes plus accrued interest thereon				2,463,216
Total	\$	730,659	\$	7,024,202

10. Fair value measurements

The carrying value of cash and cash equivalents, amounts receivable, accounts payable and accrued liabilities approximates fair value due to the short term to maturity of these instruments. The carrying value of the 10% senior convertible notes, the convertible promissory notes, and the promissory notes approximate fair value, due to the issuance of certain of these debt instruments during the three months prior and/or subsequent to the period ended September 30, 2017, under conditions substantially identical to those existing at September 30, 2017.

11. Recent accounting pronouncements

Management does not believe that any recently issued but not yet effective accounting pronouncements, if adopted, would have a material effect on the accompanying financial statements.

12. Subsequent events

We have evaluated subsequent events through the date the financial statements were issued. All material events have been disclosed.

12

Item 2. Management s Discussion and Analysis or Plan of Operations

FORWARD-LOOKING INFORMATION

We caution readers that certain important factors may affect our actual results and could cause such results to differ materially from any forward-looking statements that we make in this report. For this purpose, any statements that are not statements of historical fact may be deemed to be forward-looking statements. This report contains statements that constitute forward-looking statements. These forward-looking statements can be identified by the use of predictive, future-tense or forward-looking terminology, such as believes, anticipates, expects, estimates, plans, or similar terms. These statements appear in a number of places in this report and include statements regarding our intent, belief or current expectations with respect to many things, some of which are:

trends affecting our financial condition or results of operations for our limited history;


our business and growth strategies;

our technology;

the Internet; and

our financing plans.

We caution readers that any such forward-looking statements are not guarantees of future performance and involve significant risks and uncertainties. In fact, actual results most likely will differ materially from those projected in the forward-looking statements as a result of various factors. Some factors that could adversely affect actual results and performance include:



You should carefully consider and evaluate all of these factors. In addition, we do not undertake to update forward-looking statements after we file this report with the SEC, even if new information, future events or other circumstances have made them incorrect or misleading.

CRITICAL ACCOUNTING POLICIES

We prepare our financial statements in accordance with generally accepted accounting principles in the United States of America. The preparation of financial statements in conformity with generally accepted accounting principles requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and related disclosures of contingent assets and liabilities at the date of the financial statements, and the reported amounts of revenues and expenses during the reporting period. Significant accounting policies and methods used in preparation of the financial statements are described in note 2 to our 2016 Consolidated Financial Statements included in our Annual Report on Form 10-K for the year ended December 31, 2016. We evaluate our estimates and assumptions on a regular basis, based on historical experience and other relevant factors. Actual results could differ materially from these estimates and assumptions. The following critical accounting policies are impacted by judgments, assumptions and estimates used in preparation of our September 30, 2017 Interim Consolidated Financial Statements.

Research and development expenses:

We expense all of our research and development expenses in the period in which they are incurred. At such time as our product is determined to be commercially available, we will capitalize those development expenditures that are related to the maintenance of the commercial products, and amortize these capitalized expenditures over the estimated life of the commercial product will be based on management s estimates, including estimates of current and future industry conditions. A significant change to these assumptions could impact the estimated useful life of our commercial product resulting in a change to amortization expense and impairment charges.

Stock based compensation:

The Company accounts for its stock-based payments in accordance with FASB Accounting Standards Codification Topic 718 Compensation Stock Compensation, which requires all share-based payments, including stock options granted by the Company to its employees, to be recognized as expenses, based on the fair value of the share-based payments at the date of grant. For purposes of estimating the grant date fair value of stock-based compensation, the Company uses the Black Scholes option-pricing model, and has elected to treat awards with graded vesting as a single award. The fair value of awards granted is recognized as compensation expense on a straight-line basis over the requisite service period, which in the Company is circumstances is the stated vesting period of the award.

Financial instruments

We have issued convertible notes and convertible notes with common shares. The fair value of the convertible notes is required to be estimated as well as the fair value of the convertible notes issued with common shares. There are significant assumptions and management estimates used in determining these amounts. A significant change to these assumptions could result in a significant change to the fair value of the convertible notes.

RESULTS OF OPERATIONS

The Three months ended September 30, 2017 compared to the three months ended September 30, 2016

Revenue: We had no revenue during the three months ended September 30, 2017, nor during the three months ended September 30, 2016. Since August 1999 we have directed all of our attention towards the completion, and sales and marketing of our software applications. We believe that if we are successful in our development and sales and marketing efforts, we will generate a source of revenue in the future from sales and/or licensing of our software applications.

Selling, general and administrative expenses: Selling, general and administrative expenses consist primarily of personnel costs, professional fees, communication expenses, travel and other miscellaneous costs associated with supporting our research and development, sales and marketing and investor relations activities. During the three months ended September 30, 2017, we incurred a total of \$140,542, as compared to \$212,437 during the three months

ended September 30, 2016. There was an overall decrease in selling, general and administrative expenses of \$71,895 (34%) during the three months ended September 30, 2017 as compared to the three months ended September 30, 2016.

This decrease occurred primarily as a result of a decrease in the fair value of stock-based compensation recognized as expense during the three months ended September 30, 2017 as compared with the three months ended September 30, 2016, relating to the amortization of prepaid balances for service contracts.

We have made efforts to minimize selling, general and administrative expenses wherever possible, through measures such as reducing the number of personnel, postponing our Annual General Meeting, reducing the number of trade shows in which we participate, reducing travel costs, delaying production of new promotional material, and reducing our occupancy costs. We will continue to carefully monitor our selling, general and administrative expenses as we work within current budgetary limits leading up to the full commercial release of our products.

Research and development expenses: Research and development expenses consist primarily of personnel costs directly associated with the development of our software applications. During the three months ended September 30, 2017, we incurred a total of \$30,107, as compared to \$227,017 during the three months ended September 30, 2016 on research and development activities. There was an overall decrease in research and development expenses of \$196,910 (87%) during the three months ended September 30, 2017 as compared to the three months ended September 30, 2016.

The decrease in research and development expenses occurred as a result of a decrease in fees paid to consultants during the three months ended September 30, 2017 as compared with the three months ended September 30, 2016.

During the three months ended September 30, 2017, the primary focus of our development activity was product support during customer and prospect trials; completing version 3.3 of Validian's technology including feature and load testing.

During the three months ended September 30, 2016, the primary focus of our development activity was testing Validian's technology on a particular cloud platform, adding the ability to scale rapidly on that cloud platform, designing and architecting additional secure features and capabilities for a third module to be developed, and supporting the integration of Validian's core technology by certain channel partners and customers into their applications and solutions.

Interest and financing costs: Interest and financing costs during the three months ended September 30, 2017 and during the three months ended September 30, 2016 consisted of costs associated with our 10% senior convertible notes, our promissory notes, and our convertible promissory notes. During the three months ended September 30, 2017, we incurred \$336,800 in interest and financing costs, a decrease of \$134,312 (29%) from the \$471,112 in interest and financing costs incurred during the three months ended September 30, 2016.

The \$336,800 in interest and financing costs we incurred during the three months ended September 30, 2017 is comprised of \$75,421 of interest and prepayment bonus paid and payable to the holders of our debt; \$47,190 of accretion of our 10% senior convertible notes; \$175,437 of accretion of our convertible promissory notes; and \$38,752 of amortized deferred finance fees and original issue discount relating to the promissory notes and convertible promissory notes. The \$471,112 in interest and financing costs we incurred during the three months ended September 30, 2016 is comprised of \$158,712 of interest and prepayment bonus paid and payable to the holders of our debt; \$6,584 of accretion of our promissory notes; \$279,043 of accretion of our convertible promissory notes; and \$26,773 of amortized deferred finance fees and original issue discount relating to the promissory notes and convertible promissory notes.

We failed to settle certain of our promissory notes, 10% senior convertible notes, and convertible promissory notes, and accrued interest thereon, when they became due on various dates between October 1, 2008, and September 30, 2017; a significant portion of these notes remain in default as at September 30, 2017. In accordance with the default provision of the 10% senior convertible notes, and of the promissory notes outstanding at September 30, 2017, this has resulted in all of these notes becoming due and payable on demand as of the date of the default, or in the case of notes issued subsequent to the default, on the date of issuance, notwithstanding any other stated maturity date. Consequently, the accretion relating to the equity components of these notes issued since the initial event of default, and the amortization of any finance charges incurred thereon, has occurred in the period of issuance.

As a result of the above, the accretion components of interest and financing costs relating to the 10% senior convertible notes for the three months ended September 30, 2017, and for the three months ended September 30, 2016 relate only to notes issued during these periods. The fair value of the equity components relating to this class of notes issued during the three months ended September 30, 2017 was greater than the fair value of equity components relating to similar notes issued during the three months ended September 30, 2016, which resulted in an increase of \$47,190 (100%) in accretion related to these classes of notes.

Accretion of our convertible promissory notes decreased by \$103,606 (37%), primarily as a result of the equity component of this class of notes outstanding during the three months ended September 30, 2017 being less than the equity component of these notes outstanding during the three months ended September 30, 2016.

Interest paid and payable to the holders of our debt decreased by \$83,291 (52%), primarily as a result of an overall decrease of \$58,495 in the principal balance of our interest-bearing debt during the period from September 30, 2016 to September 30, 2017, and a decrease in prepayment bonus paid to holders of our convertible promissory notes.

Foreign exchange gain: Foreign exchange gain (loss) is comprised of realized gains and losses on foreign currency conversions, the majority of which relate to accounts payable and accrued liabilities denominated in Canadian dollars. During the three months ended September 30, 2017, the Canadian dollar gained strength relative to the United States dollar, resulting in an overall loss on foreign currency transactions of \$73,081. During the three months ended September 30, 2016, the United States dollar gained strength relative to the Canadian dollar, resulting in an overall gain on foreign currency transactions of \$18,460.

<i>Net loss:</i> We incurred a loss of \$580,530 (rounded to \$0.00 per share) for the three months ended September 30, 2017, compared to a loss of \$892,106 (rounded to \$0.00 per share) for the three months ended September 30, 2016. Our revenues and future profitability are substantially dependent on our ability to:
raise additional capital to fund operations;
license software applications to a sufficient number of clients;
be cash-flow positive on an ongoing basis;
modify the successful software applications, over time, to provide enhanced benefits to then-existing users; and
successfully develop related software applications.
15

The Nine months ended September 30, 2017 compared to the nine months ended September 30, 2016

Revenue: We had no revenue during the nine months ended September 30, 2017, nor during the three months ended September 30, 2016. Since August 1999 we have directed all of our attention towards the completion, and sales and marketing of our software applications. We believe that if we are successful in our development and sales and marketing efforts, we will generate a source of revenue in the future from sales and/or licensing of our software applications.

Selling, general and administrative expenses: Selling, general and administrative expenses consist primarily of personnel costs, professional fees, communication expenses, travel and other miscellaneous costs associated with supporting our research and development, sales and marketing and investor relations activities. During the nine months ended September 30, 2017, we incurred a total of \$382,978, as compared to \$651,936 during the nine months ended September 30, 2016. There was an overall decrease in selling, general and administrative expenses of \$268,958 (41%) during the nine months ended September 30, 2017 as compared to the nine months ended September 30, 2016.

This decrease occurred primarily as a result of a decrease in the fair value of stock-based compensation recognized as expense during the nine months ended September 30, 2017 as compared with the nine months ended September 30, 2016, relating to the amortization of prepaid balances for service contracts.

We have made efforts to minimize selling, general and administrative expenses wherever possible, through measures such as reducing the number of personnel, postponing our Annual General Meeting, reducing the number of trade shows in which we participate, reducing travel costs, delaying production of new promotional material, and reducing our occupancy costs. We will continue to carefully monitor our selling, general and administrative expenses as we work within current budgetary limits leading up to the full commercial release of our products.

Research and development expenses: Research and development expenses consist primarily of personnel costs directly associated with the development of our software applications. During the nine months ended September 30, 2017, we incurred a total of \$497,923, as compared to \$686,112 during the nine months ended September 30, 2016 on research and development activities. There was an overall decrease in research and development expenses of \$188,189 (27%) during the nine months ended September 30, 2017 as compared to the nine months ended September 30, 2016.

The decrease in research and development expenses occurred as a result of a decrease in fees paid to consultants during the nine months ended September 30, 2017 as compared with the nine months ended September 30, 2016, due

to a less extensive level of development activity undertaken.

During the nine months ended September 30, 2017, the primary focus of our development activity was completing the development of the migration to the Red Hat Enterprise Linux operating system, including SDK's for C++ and Java and testing; completing the development of the migration to the Apple iOS operating system including SDK's for Objective-C and Swift and testing; supporting the trial release of a customer's Validian-enabled application; testing Validian s technology on a particular cloud platform, adding the ability to scale rapidly on that cloud platform, designing and architecting more secure features and capabilities for a third module to be developed and supporting the integration of Validian s core technology by certain channel partners into their applications and solutions; product support during customer and prospect trials; and completing version 3.3 of Validian's technology including feature and load testing.

During the nine months ended September 30, 2016, the primary focus of our development activity was migrating Validian's technology to particular cloud platforms; migrating Validian's technology to certain Linux platforms; supporting the development of added features into a customer's mobile communications application; developing a second module of secure features and capabilities that can be integrated rapidly into existing or new applications and solutions; and supporting the integration of Validian's core technology by certain channel partners into their applications and solutions.

Interest and financing costs: Interest and financing costs during the nine months ended September 30, 2017 and during the nine months ended September 30, 2016 consisted of costs associated with our 10% senior convertible notes, our promissory notes, and our convertible promissory notes. During the nine months ended September 30, 2017, we incurred \$891,641 in interest and financing costs, a decrease of \$224,605 (20%) from the \$1,116,246 in interest and financing costs incurred during the nine months ended September 30, 2016.

The \$891,641 in interest and financing costs we incurred during the nine months ended September 30, 2017 is comprised of \$152,403 of interest and prepayment bonus paid and payable to the holders of our debt; \$63,577 of accretion of our 10% senior convertible notes; \$613,874 of accretion of our convertible promissory notes; \$3,679 of accretion of our promissory notes; and \$58,109 of amortized deferred finance fees and original issue discount relating to the promissory notes and convertible promissory notes. The \$1,116,246 in interest and financing costs we incurred during the nine months ended September 30, 2016 is comprised of \$513,469 of interest and prepayment bonus paid and payable to the holders of our debt; \$18,079 of accretion of our 10% senior convertible notes; \$533,597 of accretion of our convertible promissory notes; \$6,584 of accretion of our promissory notes; and \$44,517 of amortized deferred finance fees and original issue discount relating to the convertible promissory notes.

We failed to settle certain of our promissory notes, 10% senior convertible notes and convertible promissory notes, and accrued interest thereon, when they became due on various dates between October 1, 2008, and September 30, 2017; a significant portion of these notes remain in default as at September 30, 2017. In accordance with the default provision of the 10% senior convertible notes, and of the promissory notes outstanding at September 30, 2017, this has resulted in all of these notes becoming due and payable on demand as of the date of the default, or in the case of notes issued subsequent to the default, on the date of issuance, notwithstanding any other stated maturity date. Consequently, the accretion relating to the equity components of these notes issued since the initial event of default, and the amortization of any finance charges incurred thereon, has occurred in the period of issuance.

As a result of the above, the accretion components of interest and financing costs relating to the 10% senior convertible notes for the nine months ended September 30, 2017, and for the nine months ended September 30, 2016 relate only to notes issued during these periods. The fair value of the equity components relating to this class of notes issued during the nine months ended September 30, 2017 was greater than the fair value of equity components relating to similar notes issued during the nine months ended September 30, 2016, which resulted in an increase of \$45,498 (252%) in accretion related to these classes of notes.

Accretion relating to the promissory notes decreased by \$2,905 (44%) as a result of the value of the equity components relating to these notes being lower during the nine months ended September 30, 2017 as compared to the nine months ended September 30, 2016.

Accretion of our convertible promissory notes increased by \$80,277 (15%) primarily as a result of the equity component of this class of notes outstanding during the nine months ended September 30, 2016 being greater than the equity component of these notes outstanding during the nine months ended September 30, 2017.

Interest and prepayment bonus paid and payable to the holders of our debt decreased by \$361,066 (70%), primarily as a result of an overall decrease of \$58,495 in the principal balance of our interest-bearing debt during the period from September 30, 2016 to September 30, 2017, and a decrease in prepayment bonus paid to holders of our convertible

promissory notes

Loss on extinguishment of debt: During the nine months ended September 30, 2016, we issued Class A, Class B and Class C convertible stock in settlement of certain of the 10% senior convertible notes and accrued interest thereon. There was an aggregate loss on these financing transactions of \$1,750,554. We also settled \$6,000 in accounts payable and accrued liabilities by issuing common stock, which resulted in a gain of \$260 on the settlement. There were no comparable transactions during the nine months ended September 30, 2015.

Foreign exchange gain: Foreign exchange gain (loss) is comprised of realized gains and losses on foreign currency conversions, the majority of which relate to accounts payable and accrued liabilities denominated in Canadian dollars. During the nine months ended September 30, 2017, and during the nine months ended September 30, 2016, the Canadian dollar gained strength relative to the United States dollar, resulting in an overall loss on foreign currency transactions of \$135,200 and \$77,438, respectively.

Net loss: We incurred a loss of \$1,907,742 (rounded to \$0.00 per share) for the nine months ended September 30, 2017, compared to a loss of \$4,282,026 (rounded to \$0.01 per share) for the nine months ended September 30, 2016. Our revenues and future profitability are substantially dependent on our ability to:

raise additional capital to fund operations;

license software applications to a sufficient number of clients;

be cash-flow positive on an ongoing basis;

modify the successful software applications, over time, to provide enhanced benefits to then-existing users; and

successfully develop related software applications.

LIQUIDITY AND CAPITAL RESOURCES

General: Since inception, we have funded our operations from private placements of debt and equity securities. In addition, until September 1999 we derived revenues from consulting contracts with affiliated parties, the proceeds of which were used to fund operations. We have also received an aggregate of \$791,650 in proceeds relating to VAR licensing agreements. Until such time as we are able to generate adequate revenues from the licensing of our software applications, we cannot assure that we will be successful in raising additional capital, or that cash from the issuance of debt securities, the exercise of existing warrants and options, and the placements of additional equity securities, if any, will be sufficient to fund our long-term research and development and selling, general and administrative expenses.

Our cash and cash equivalents decreased by \$191,604 during the nine months ended September 30, 2017, from a balance of \$191,764 at December 31, 2016, to \$160 at September 30, 2017. This decrease in cash occurred due to our net loss of \$1,907,742, which resulted in net cash used in operations of \$506,839 during the period, partially offset by \$315,235 in net proceeds from financing activities. We issued \$321,000 of our convertible promissory notes, from which \$29,500 in issuance costs and original issue discount was deducted; \$151,235 of our 10% senior convertible notes; and \$31,000 of our promissory notes; and we repaid \$82,500 of our promissory notes, \$71,000 of our convertible promissory notes, and \$5,000 of our 10% senior convertible notes.

We added an explanatory paragraph to our interim consolidated financial statements for the nine months ended September 30, 2017. It states that our economic viability is dependent on our ability to finalize the development of our principal products, generate sales and finance operational expenses, and that these factors, together with our lack of revenues to date; our negative working capital; our loss for the year, as well as negative cash flow from operating activities in the same period; and our accumulated deficit, raise substantial doubt regarding our ability to continue as a going concern. At September 30, 2017, we had negative working capital of \$4,619,522 and an accumulated deficit of \$54,568,158; for the nine months then ended we had a net loss of \$1,907,742, and negative cash flow from operations of \$506,839. Furthermore, the Company failed to settle certain of its 10% senior convertible notes, promissory notes and convertible promissory notes, plus accrued interest thereon when they matured on various dates from October 1, 2008 to September 30, 2017. A substantial amount of these notes remain unpaid as of September 30, 2017. All of the 10% senior convertible notes, as well as the promissory notes, were in default at September 30, 2017 in accordance with the default provisions of the respective notes, and as a result are due and payable on demand.

We anticipate commercial sales during the first quarter of 2018, however we cannot be assured that this will be the case. During the nine months ended September 30, 2017, we did not engage any additional personnel. During the next nine months we expect to engage one officer and director; we do not expect to hire additional personnel unless we are successful in raising significant funds through the issuance of our debt or equity securities. We do not expect to make any material commitments for capital equipment expenditures during the next twelve months.

We have an immediate requirement for additional working capital in order to proceed with our business plan. We review our cash needs and sources on a month-to-month basis and we are currently pursuing appropriate opportunities to raise additional capital to fund operations. Additional sources of capital could involve issuing equity or debt securities. We have engaged consultants to provide advice to us with respect to the raising of capital. However, additional funding may not be available to us on reasonable terms, if at all. The perceived risk associated with the possible sale of a large number of shares of our common stock could cause some of our stockholders to sell their stock, thus causing the price of our stock to decline. In addition, actual or anticipated downward pressure on our stock price due to actual or anticipated issuance of stock could cause some institutions or individuals to engage in short sales of our common stock, which may itself cause the price of our stock to decline. We may be unable to raise additional capital if our stock price is too low. A sustained inability to raise capital could force us to limit or curtail our operations.

We expect the level of our future operating expenses to be driven by the needs of our research and development and marketing programs, offset by the availability of funds. In addition, we have since inception taken steps to keep our expenses relatively low and conserve available cash until we begin generating sufficient operating cash flow.

Sources of Capital: Our principal sources of capital for funding our business activities have been the private placements of debt and equity securities. During the nine months ended September 30, 2017, we issued \$291,500, net of original issue discount and finance fees, of our convertible promissory notes; \$151,235 of our 10% senior convertible notes, and \$31,000 of our promissory notes, which generated cash to fund operations. We also issued 78 Series C convertible preferred shares and \$60,000 of our 10% senior convertible notes in settlement of accounts payable and accrued liabilities, which reduced our requirement for cash settlement of the respective liabilities. During this period, we also issued an aggregate of 115,374,761 shares of our common stock in settlement of \$571,887 of our convertible promissory notes plus \$20,771 in accrued interest thereon, which reduced the amount of cash that would otherwise have been required to settle these liabilities.

Uses of Capital: Over the past several years, we have scaled our development activities to the level of available cash resources. Our plans with respect to future staffing will be dependent upon our ability to raise additional capital. We have not entered into any off-balance sheet arrangements which would have resulted in our use of capital.

ITEM 3. QUANTITATIVE AND QUALITATIVE DISCLOSURES ABOUT MARKET RISK

N/A

ITEMS 4 AND 4T. CONTROLS AND PROCEDURES

Evaluation of Disclosure Controls and Procedures

An evaluation was carried out under the supervision and with the participation of our management, including our Chief Executive Officer and Chief Financial Officer, of the effectiveness of the design and operation of our disclosure controls and procedures (as defined in Rules 13a-15(e) and 15d-15(e) under the Securities Exchange Act of 1934, as amended (the Exchange Act)) as of the end of the period covered by this report. Based on the evaluation of our disclosure controls and procedures, our Chief Executive Officer and Chief Financial Officer has concluded that our disclosure controls and procedures were not effective to ensure that the information required to be disclosed by us in the reports that we file or submit under the Exchange Act was recorded, processed, summarized and reported within the time periods specified in the SEC s rules and forms and that such information required to be disclosed is accumulated and communicated to management, including our Chief Executive Officer and Chief Financial Officer, to allow timely decisions regarding required disclosure.

Changes in Internal Control over Financial Reporting

There were no changes in our internal control over financial reporting that occurred during the nine months ended September 30, 2017 that have materially affected, or are reasonably likely to materially affect, our internal control over financial reporting.

Management s Report on Internal Controls over Financial Reporting

At December 31, 2016, management of the Company provided a report on internal controls over financial reporting. Reference should be made to our annual report on Form 10-K for that report, wherein we reported that management s assessment at December 31, 2016 was that the Company s internal control over financial reporting was not effective to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with U.S. generally accepted accounting principles.

In connection with the preparation of the consolidated financial statements for the year ended December 31, 2016, our management identified the existence of certain significant internal control deficiencies that they considered to be material weaknesses. In particular, the following weaknesses in our internal control system were identified at December 31, 2016: (1) a lack of segregation of duties; (2) the lack of timely preparation of certain back up schedules; (3) finance staff s lack of sufficient technical accounting knowledge; (4) a lack of independent Board oversight; and (5) signing authority with respect to corporate bank accounts. A material weakness is a significant deficiency in one or more of the internal control components that alone or in the aggregate precludes our internal controls from reducing to an appropriately low level of risk that material misstatements in our financial statements will not be prevented or detected on a timely basis. We considered these matters in connection with the period-end closing of accounts and preparation of the related consolidated financial statements and determined that no prior period financial statements were materially affected by such matters.

Our size has prevented us from being able to employ sufficient resources at this time to enable us to have an adequate level of supervision and segregation of duties within our internal control system. We will continue to monitor and assess the costs and benefits of additional staffing within the Company.

We were unable to eliminate the identified weaknesses with respect to the period covered by this report. Set forth below is a discussion of the significant internal control deficiencies which have not been remediated.

Lack of segregation of duties. Since commencing the development phase of our operations in August 1999, our size has prevented us from being able to employ sufficient resources to enable us to have an adequate level of supervision and segregation of duties within our internal control system. Our accountant is the only person involved in the data entry function, and since the departure of our chief financial officer in 2008, our chief executive officer has assumed the role of chief financial officer. We are inadequately staffed at this time to ensure a sufficient level of segregation of duties. As a result, this significant internal control deficiency had not been remediated as of the end of the period covered by this report, nor do we know if we will be able to remediate this weakness in the foreseeable future. However, we will continue to monitor and assess the costs and benefits of additional staffing.

Lack of timely preparation of back up schedules. Throughout 2016, we were able to complete most of our back up schedules in a timely manner, however, during this time we consistently experienced a lack of complete preparedness at the time our external independent accountants commenced their field work on a quarterly basis. As such, we believe that this material weakness had not been remediated as of the end of the period covered by this report. Inasmuch as this deficiency is related to our lack of adequate staffing, which is a condition which our size prohibits us from remediating, we do not know if we will be able to remediate this weakness in the foreseeable future. We will continue to review our interim procedures, and to make changes wherever practicable to assist in remediating this deficiency.

Finance staff s lack of sufficient technical accounting knowledge. Due to the limited number of personnel, our finance staff does not have sufficient technical accounting knowledge to address all complex and non-routine accounting transactions that may arise. These transactions are sometimes extremely technical in nature and require an in-depth understanding of generally accepted accounting principles. As a result of this pervasive deficiency, these types of transactions may not be recorded correctly, potentially resulting in material misstatements of the financial statements of the Company. To address this risk, the Company has a control whereby it consults with its auditors and advisors, as needed, in conjunction with the recording and reporting of complex and non-routine accounting transactions. Management has concluded that this control was operating effectively during the preceding year, as the Company consulted with external advisors on certain complex and non-routine transactions resulting in no material misstatements being identified during the year end audit. Although management has determined that this control was operating effectively during the year ended December 31, 2016, the finance staff s lack of sufficient technical accounting knowledge nonetheless remains a continued weakness in our internal control system. Any changes in the staff complement will be dependent upon the growth of our operations and the number of our staff to allow further technical accounting knowledge to address all complex and non-routine accounting transactions. Management will continue to review existing consultation controls and, if appropriate, implement changes to its current internal control processes whereby more effective consultation will be performed.

Lack of independent Board oversight. Our Board of Directors consists of only one individual who is also the Company s sole signing officer. We have experienced difficulties in identifying suitable candidates to serve as independent Board members because of our size, the perceived additional liability to the public by prospective candidates and the excessive additional costs associated with the selection of a candidate including director fees and director liability insurance. As such, our Board lacks the controls, depth of knowledge and perspective that such independence would provide.

Signing authority with respect to corporate bank accounts. Since the departure of our Chief Financial Officer and Treasurer in July 2008, the positions of Director, President, Chief Executive Officer, Chief Financial Officer, Executive Vice President, Secretary and Treasurer have been held by one person. This individual has sole signing authority for the Company s bank accounts. Our Accountant monitors our bank accounts on a regular basis, however there can be no assurance that unauthorized or unsupported transactions will not occur.

If we are unable to remediate the identified material weakness, there is a more than remote likelihood that a material misstatement to our SEC reports will not be prevented or detected, in which case investors could lose confidence in the accuracy and completeness of our financial reports, which could have an adverse effect on our ability to raise additional capital and could also have an adverse effect on our stock price.

PART II OTHER INFORMATION

Item 1. Legal Proceedings
None
Item 1a. Risk Factors
In addition to other information set forth in this Report, you should carefully consider the risk factors previously disclosed in Item 1A. to Part 1 of our Annual Report on Form 10-K for the year ended December 31, 2016. There were no material changes to these risk factors during the nine months ended September 30, 2017.
Item 2. Unregistered Sales of Equity Securities and Use of Proceeds
None
Item 3. Defaults upon Senior Securities
We failed to settle certain of our 10% senior convertible notes, our promissory notes and our convertible promissory

notes, plus accrued interest thereon when they matured on various dates between October 1, 2008 and September 31, 2017. A significant amount of these notes remained unpaid as of September 30, 2017, and were therefore in default and due and payable on demand. Additionally, in accordance with the default provisions of the notes, this failure to settle the matured notes resulted in the remaining 10% senior convertible notes and accrued interest thereon becoming also due and payable on demand. Notwithstanding our obligation to repay these amounts immediately, the note holders have verbally communicated to management their willingness to continue holding the notes until new terms are negotiated. We will accrue interest on these unpaid balances at the coupon rate until a settlement is reached.

Until such time as the matured notes plus accrued interest thereon are settled, all of the 10% senior convertible notes and the promissory notes will remain in default.

Item 4. Min	e Safety Disclosures
Not applicab	le.
Item 5. Oth	er Information
	er 16, 2016, Validian Corporation (Validian) entered into a Software Licensing Agreement for licensing and deployment of Validian's technology in a mobile messaging application.
Item 6. Exh	ibits
(a) Exhibits.	
31.1 31.2 32.1 32.2 101	Certification of Chief Executive Officer Pursuant to Section 302 of the Sarbanes-Oxley Act of 2002 Certification of Chief Financial Officer Pursuant to Section 302 of the Sarbanes-Oxley Act of 2002 Certification of Chief Executive Officer Pursuant to Section 906 of the Sarbanes-Oxley Act of 2002 Certification of Chief Financial Officer Pursuant to Section 906 of the Sarbanes-Oxley Act of 2002 The following financial information from our Quarterly Report on Form 10-Q for the quarter ended September 30, 2017 formatted in Extensible Business Reporting Language (XBRL): (i) the Balance Sheets, (ii) the Statements of Operations, (iii) the Statements of Cash Flows, and (iv) Notes to Financial Statements
	21

SIGNATURES

In accordance with requirements of the Securities Exchange Act of 1934, the registrant has duly caused this Report to be signed on its behalf by the undersigned, thereunto duly authorized.

VALIDIAN CORPORATION

By: /s/ Bruce Benn

Bruce Benn

President, Chief Executive Officer

and Chief Financial officer

(principal executive officer)

Dated: November 20, 2017

In accordance with the Securities Exchange Act of 1934, this Report has been signed below by the following persons on behalf of the registrant and in the capacities and on the dates indicated.

By: /s/ Bruce Benn

Bruce Benn

President, Chief Executive Officer

and Chief Financial officer

(principal financial and accounting officer)

Dated: November 20, 2017